Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: NPH human insulin Clear all

Conditions: Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk
Interventions: Patient-led Insulin (intervention group), Provider-led Insulin (standard care); Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Gestational Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin Detemir, Insulin NPH; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes
Interventions: Wosulin N, Novolin N; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
Interventions: Subcutaneous Insulin, Inhaled Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 77 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 77
States / cities: Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 59 more

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Canakinumab 150 mg, Placebo to Canakinumab; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more

Conditions: Diabetes Mellitus
Interventions: 30% Regular Insulin Human Neutral and 70%Isophane Insulin, Novolin 70/30; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions: Metformin, Insulin; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 26
States / cities: Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 20 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir, insulin NPH; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin detemir, Insulin NPH, Diet/exercise; Drug · Behavioral
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more

Conditions: Type 1 Diabetes, Dawn Phenomenon
Interventions: Lantus (glargine); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma, Diabetes Mellitus
Interventions: Inhaled Insulin, Subcutaneous Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 86
States / cities: Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 64 more

Conditions: Kidney Transplantation, Diabetes, Hyperglycemia
Interventions: insulin, NPH Insulin or glargine insulin and aspartame insulin; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Type 2 Diabetes
Interventions: Detemir + aspart insulin before meals, NPH insulin + regular insulin; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Atlanta, Georgia • Chicago, Illinois

Conditions: Glucose, Blood
Interventions: IICE Dosing, Healthcare Provider dosing; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine at bedtime instead of NPH, NPH twice-daily; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, Lispro Low Mix, Lispro Mid Mix, Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 30 Years to 79 Years
Enrollment: 2,091 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 138
States / cities: Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more

Conditions: Diabetes Mellitus
Interventions: NPH, Correction Factor; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years to 79 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2963016, LANTUS®, Oral Antihyperglycemic Medication; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Neutral Protamine Hagedorn (NPH), Detemir insulin; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hyperglycemia, Diabetes Mellitus
Interventions: Glargine insulin, Lispro insulin, NPH Insulin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773 placebo, BI 10773 low dose, BI 10773 high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Glargine insulin, NPH insulin and regular insulin, lispro insulin; Drug
Lead sponsor: Cook County Health; Government
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gestational Diabetes, Pregnancy Related
Interventions: Insulin; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Rochester, New York • Philadelphia, Pennsylvania

Conditions: Diabetes During Pregnancy
Interventions: NPH, Insulin LISPRO, Insulin glulisine; Drug
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Santa Barbara, California

Search by objective public record fields.

Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)

DETERMINE: Detemir vs NPH

Comparative Glucose Clamp Study of Wockhardt's Human Isophane Insulin With Novolin N,in Healthy Subjects

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma

IV Insulin Protocol in Diabetes and Renal Transplantation

Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes

Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients

Insulin Glargine Versus Twice-Daily NPH

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

Inpatient Diabetes on Corticosteroids

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy

The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Insulin Therapy in the Hospital Comparing Two Protocols

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)

Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes